
President and COO, G & W LABORATORIES, INC.
Member of the Healthcare Council
Kurt Orlofski, CPA, CMA, is President and COO at G & W Laboratories. Mr. Orlofski was previously, President of Wockhardt USA (Apr 2007 - Aug 2009). Wockhardt is a global leader in pharmaceuticals and biotechnology. Previously, Mr. Orlofski was President and Chief Executive Officer of Pliva, the US subsidiary of the global specialty pharmaceutical company Pliva. He was responsible for all Pliva US businesses including USD300m of generics business. Previously, Mr. Orlofski was Senior Vice President of Global Business Development at Alpharma Human Pharmaceuticals. His areas of expertise include pharmaceutical general management, operations and quality management, sales and marketing in generics, new business unit start-ups, product acquisition, brand and generic in and out licensing of products and technology, business unit and asset sales and acquisitions including integration, contract manufacturing deals in and out, and negotiation and execution of supplier and customer supply agreements. (This is me - Update Profile)
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
Lupin acquisition in Japan a positive
October 16, 2007
Indian Drug Maker Lupin to Acquire Kyowa Pharmaceutical | www.pipelinereview.com
Japan is the second largest generic market in the world. Kyowa Pharmaceuticals has a real presence in the Japanese pharmaceutical market. Allows Kyowa to leverage low cost Indian manufacturing while Lupin gains a large and growing market for distribution.
| Study Group Name | No. Members |
|---|---|
| Generic Drug Economic Experts | 890 |
Kurt Orlofski has not participated in any GLG Live Meetings.